Month: March 2025

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate developments. “We are thrilled our cadisegliatin clinical program can resume following the lifting of the clinical hold by the U.S. Food and Drug...

(Dollar amounts are in thousands, in Canadian currency unless otherwise specified) GUELPH, Ontario, March 20, 2025 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS”) (TSX: HPS.A) a leading manufacturer of dry-type transformers, power quality products and related magnetics, today announced its financial results for the fourth quarter 2024. HIGHLIGHTSRecord sales of $208 million in the quarter, an increase of 11.5% versus 2023. Year-to-date sales were $788 million, an increase of 11% versus 2023. Adjusted EBITDA of $32,548 in the quarter, or 15.6% of sales. Year-to-date Adjusted EBITDA is $130,484, or 16.6% of sales. Gross margin of 32.7% for the quarter, 32.8% year-to-date. Net earnings of $23.7 million and earnings per share of $1.99 for quarter 4, 2024. Net earnings of $71.5 million and earnings per share of $6.01 year-to-date...

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended December 31, 2024. “The fourth quarter of 2024 was marked by key strategic decisions and solid pipeline progress,” said Kristen Fortney,...

Fortified Balance Sheet of $113.0 Million Enables Company to continue R&D activities in AI-Driven Customer Platform in other Corporate Initiatives 2024 Annual Meeting of Stockholders Scheduled for May 6, 2025 AUSTIN, Texas, March 20, 2025 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a leader in enterprise cloud solutions for mobile applications, today reported financial results for the year ended December 31, 2024. Financial HighlightsFor the year ended December 31, 2024, net loss from continuing operations was $10.3 million, as compared to $41.9 million in the previous period, while adjusted EBITDA loss improved to $10.3 million for the year ended December 31, 2024, compared to $15.5 million in the previous year period. Net cash used in operations was $13.3 million for the year ended December...

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, “We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a strengthened financial position, and enhancements to our leadership team, all aligning with our mission to develop innovative T cell-engaging bispecific...

Geneva, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) — Schedules Conference Call and Webcast for Monday, March 24 at 10:00 am ET (3:00 pm CET)Ends the year with a strong cash position of approximately $85 million FY 2024 $11 million revenue reflects the industry-wide transition from traditional semiconductors to next-generation Quantum Resistant chips Expects a return to growth in FY 2025 Continues R&D investments with $7.2 million allocated in 2025, up from $5 million in 2024 Confirmed bookings of $6.8 million as of March 20, 2025, reflecting strong YoY growth $93 million in projected contract pipeline over next three years from 2026 to 2028 Executing a multi-faceted organic growth, investment and acquisition strategySEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses...